Fate Therapeutics, Inc. (FATE) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs.
Analysis Summary
Fate Therapeutics, Inc. reported revenue of $6.6M in the most recent fiscal year, growing at a 5-year CAGR of -26.7%.
Trailing-twelve-month margins: gross margin -343.0%, operating margin -20.6%, net margin -19.4%.
At the current price of $2.44, FATE has negative trailing earnings (P/E not meaningful) and an ROE of -65.08%. Market capitalisation stands at $284M.
Balance sheet quality for FATE: current ratio of 5.8, net cash position of $125.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $2.44 |
| Market Cap | $284M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.96 |
| EV / EBITDA | -2.84 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -65.08% |
| Return on Invested Capital | -57.47% |
| Return on Assets | -48.44% |
| Gross Margin | -343.01% |
| Operating Margin | -2058.08% |
| Net Margin | -1941.09% |
Financial Health
| Debt / Equity | 0.49 |
| Current Ratio | 4.85 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -6.97 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| FATE | Fate Therapeutics, Inc. | $284M | 1.96 | -65.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -4.69% |
| 3 months | +16.75% |
| Year-to-date | +148.32% |
| 1 year | +156.84% |
| 3 years | -4.31% |
| 5 years | -96.59% |
52-Week Range
| 52-week High | $3.23 |
| 52-week Low | $0.94 |
| Avg Volume (90d) | 3.1M |
Related companies: ABOS · ALEC · CRBP · INO · MOLN · NKTX · PEPG
Explore sector: Healthcare · Biotechnology
More sections of FATE: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks